1,241 Shares in Humana Inc. (NYSE:HUM) Purchased by Opinicus Capital Inc.

Opinicus Capital Inc. bought a new position in shares of Humana Inc. (NYSE:HUM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,241 shares of the insurance provider’s stock, valued at approximately $568,000.

Other hedge funds have also recently bought and sold shares of the company. Mariner LLC grew its holdings in Humana by 2.3% during the third quarter. Mariner LLC now owns 14,119 shares of the insurance provider’s stock worth $6,869,000 after acquiring an additional 312 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Humana by 27.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 27,943 shares of the insurance provider’s stock worth $13,595,000 after acquiring an additional 6,034 shares during the period. Silverarc Capital Management LLC acquired a new position in Humana during the third quarter worth about $4,865,000. Vest Financial LLC increased its stake in Humana by 43.3% in the 4th quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider’s stock worth $12,815,000 after purchasing an additional 8,455 shares in the last quarter. Finally, Artemis Investment Management LLP increased its stake in Humana by 9.6% in the 4th quarter. Artemis Investment Management LLP now owns 64,573 shares of the insurance provider’s stock worth $29,563,000 after purchasing an additional 5,672 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

HUM traded down $5.51 on Friday, hitting $305.90. The company had a trading volume of 1,213,131 shares, compared to its average volume of 1,914,716. The company’s fifty day moving average price is $327.77 and its 200 day moving average price is $394.49. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59. The stock has a market cap of $36.86 billion, a price-to-earnings ratio of 19.05, a price-to-earnings-growth ratio of 1.82 and a beta of 0.45.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period in the previous year, the company earned $9.38 EPS. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. Equities analysts predict that Humana Inc. will post 16.07 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.16%. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HUM. StockNews.com cut Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 26th. Mizuho dropped their price target on Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, January 26th. Argus cut Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Cantor Fitzgerald dropped their price target on Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, The Goldman Sachs Group decreased their price objective on Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research report on Wednesday, April 3rd. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $433.74.

Insider Buying and Selling

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, with a total value of $200,064.05. Following the transaction, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.